Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1

4(66.7%)

Phase 3

1(16.7%)

Phase 2

1(16.7%)

6Total

Phase 1(4)

Phase 3(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04771572Phase 1Recruiting

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

Role: lead

NCT07342478Phase 3Recruiting

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Role: lead

NCT04775745Phase 1Recruiting

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Role: lead

NCT04139434Phase 1Completed

Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML

Role: lead

NCT06978088Phase 2Recruiting

LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

Role: collaborator

NCT04356846Phase 1Unknown

A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma

Role: collaborator

All 6 trials loaded